Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision label updated to v3.4.3. The previous label v3.4.2 has been removed.
    Difference
    0.0%
    Check dated 2026-03-07T17:21:33.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a minor maintenance update and does not change study information; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T04:43:52.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.0 to v3.4.1. This change does not affect any study details, eligibility criteria, results, or timeframes.
    Difference
    0.0%
    Check dated 2026-02-07T03:50:57.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Glossary display added; metadata labels updated to show Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the previous QC label, FEAR Act data label, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-23T20:19:50.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4; no core study information or user-facing elements were altered.
    Difference
    0.0%
    Check dated 2026-01-16T20:22:34.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The study locations were expanded with new sites across several US states and international sites (Western Australia, Alicante, Madrid). The HHS Vulnerability Disclosure link was removed and the page revision was updated to v3.3.3.
    Difference
    2%
    Check dated 2025-12-18T23:24:08.000Z thumbnail image

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.